CDKN2B-AS1 as a novel therapeutic target in cancer: Mechanism and clinical perspective.

Biochemical pharmacology 2023 Jul

filter terms:

Long non-coding RNAs (lncRNA) have been identified as essential components having considerable modulatory impactson biological activities through altering gene transcription, epigenetic changes, and protein translation. Cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1), a recently discovered lncRNA, was shown to be substantially elevated in various cancers.Furthermore, via modulation ofvarious signalingaxes, it is effectively connected to the control of critical cancer-associatedbiological pathways likecell proliferation, apoptosis, cell cycle, epithelial-mesenchymal transition(EMT), invasion, and migration. Considering the crucial functions ofCDKN2B-AS1in cancer onset and development, this lncRNA offers immense therapeutic implications for usage as a new diagnostic or treatment approach. In this article, we evaluate the most recent discoveries made into the functions of the lncRNA CDKN2B-AS1 in cancer, in addition to its prospect asbeneficial properties,prognostic anddiagnostic biomarkersin the cancer-related treatment, emphasizingits participation in a broad network of signalingaxes whichcould affectvariouscancers and investigating its promising therapeutic possibility. Copyright © 2023 Elsevier Inc. All rights reserved.

Citation

Ahmed Hjazi, Eishah Ghaffar, Waqas Asghar, Hasan Alauldeen Khalaf, Muhammad Ikram Ullah, Rosario Mireya Romero-Parra, Beneen M Hussien, Adeeb Abdulally Abdulhussien Alazbjee, Yashwant Singh Bisht, Yasser Fakri Mustafa, Seyed Reza Hosseini-Fard. CDKN2B-AS1 as a novel therapeutic target in cancer: Mechanism and clinical perspective. Biochemical pharmacology. 2023 Jul;213:115627